New York, May 14, 2021
avoMD, a next-gen clinical guidelines and decision support platform, announced today it is further expanding its presence in Asia with the opening of a subsidiary in South Korea. This strategic initiative stems from increased demand among leading hospitals and clinical stakeholders in the Korean market.
“avoMD’s expansion into the Korean market will enhance our ability to serve the increasing demand for our products and services,” said Dr. Joongheum Park, Chairman & CTO of avoMD. “Health tech has been a key growth sector in South Korea, and this initiative will allow us to scale our team and customer base in an exciting new market.”
avoMD first entered the Korean market in early 2020 through a formal collaboration with Samsung Medical Center, where avoMD integrated its platform into Samsung’s electronic health record to deliver interactive, just-in-time decision support to clinicians.
avoMD is building the next-gen platform for interactive clinical guidelines and decision support. Leading provider organizations use avoMD to digitize their clinical workflows and algorithms and put them in the hands of their providers instantly. The technology functions on a standalone basis via web and mobile apps, or can integrate into the EHR. In usability trials and live deployments, the software has been shown to dramatically increase clinical guideline usability and usage. Led by a team of physicians and informaticians from Harvard, Yale and Mount Sinai, avoMD has over 10 current hospital and urgent care partners including Children’s Minnesota, PM Pediatrics, and Samsung Medical Center.
For more information, visit http://www.avomd.io.